Bayer will present a range of new clinical data at the American College of Cardiology’s 71st Annual Scientific Session (ACC.22), being held April 2-4, 2022, in Washington, D.C. Data from KERENDIA® (finerenone), a first-in-class nonsteroidal mineralocorticoid receptor antagonist (MRA)1 and asundexian, an investigational oral Factor XIa inhibitor2 will be presented at the meeting. These data highlight Bayer’s ongoing commitment to patients with cardiovascular (CV) and kidney diseases.

At least one model from the University of Washington’s Institute for Health Metrics and Evaluation estimates that at this time, 73 percent of Americans are immune to Omicron, and it could rise to 80 percent by mid-March.

Coronavirus infection during pregnancy does not appear to affect infants’ brain function, but the pandemic itself may be having an impact, a study published on January 4 in JAMA Pediatrics suggests. Additionally, new laboratory research found the coronavirus can directly damage the kidneys by initiating a cascade of molecular events that leads to scarring.

Surgeons from NYU Langone Health hit a major milestone in transplantation science after successfully attaching a pig’s kidney to a human patient and watching it work for several hours. 

Shares of Avrobio were up in trading after the company posted positive clinical data from gene therapy trials in three different rare lysosomal diseases: Fabry, Gaucher type 1 and cystinosis.

A roundup of some of the latest scientific studies on the novel coronavirus and efforts to find treatments and vaccines for Covid-19 includes research on long-lasting Covid-19 effects seen in children.

The U.S. Food and Drug Administration approved GlaxoSmithKline plc’s Benlysta (belimumab) for the treatment of adult patients with active lupus nephritis who are receiving standard therapy.

Novartis received the U.S. Food and Drug Administration’s Breakthrough Therapy tag for the company’s experimental medicine iptacopan, which the Swiss drugmaker hopes wins approval to treat the rare blood disorder paroxysmal nocturnal hemoglobinuria.

The U.S. Food and Drug Administration (FDA) approved Alnylam Pharmaceuticals’ Oxlumo (lumasiran) for primary hyperoxaluria type 1 (PH1) to lower urinary oxalate levels in children and adults.

Shares of Calliditas Therapeutics soared in trading after the company announced positive Phase III data from a study of Nefecon in IgA nephropatjhy (IgAN), an autoimmune renal disease.